Compare · GILD vs WINT
GILD vs WINT
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Windtree Therapeutics Inc. (WINT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and WINT operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD carries a market cap of $206.55B.
- GILD has hit the wire 22 times in the past 4 weeks while WINT has been quiet.
- GILD has more recent analyst coverage (25 ratings vs 0 for WINT).
- Company
- Gilead Sciences Inc.
- Windtree Therapeutics Inc.
- Price
- -
- -
- Market cap
- $206.55B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- News (4w)
- 22
- 0
- Recent ratings
- 25
- 0
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Windtree Therapeutics Inc.
Windtree Therapeutics, Inc., a clinical-stage biotechnology and medical device company, focuses on the development of therapeutics for the treatment of acute pulmonary and cardiovascular diseases. Its lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company has a collaboration with University of Milan-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. operates as a subsidiary of Lee's Pharmaceutical Holdings Limited.
Latest GILD
- Chief Comm & Corp Aff Officer Johanna Mercier exercised 25,000 shares at a strike of $72.34 and sold $4,775,527 worth of shares (28,000 units at $170.55) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 110,684 units (SEC Form 4)
- Chief Financial Officer Andrew D Dickinson sold $514,410 worth of shares (3,000 units at $171.47) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 158,096 units (SEC Form 4)
- Kernal Bio Announces Strategic Investment from IFLI and Leadership Appointments
- Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing
- Director Kramer Kelly A. exercised 10,376 shares at a strike of $66.92 and sold $1,761,437 worth of shares (10,376 units at $169.76) as part of a pre-agreed trading plan (SEC Form 4)
- A Run of FDA Target Dates Fills the Biotech Calendar From Late November to Year End
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M sold $557,810 worth of shares (3,399 units at $164.11) as part of a pre-agreed trading plan, decreasing direct ownership by 39% to 5,360 units (SEC Form 4)
- Gabelli Releases Agenda for 8th Annual Healthcare Symposium
- Chairman & CEO O'Day Daniel Patrick exercised 112,429 shares at a strike of $72.34 and sold $19,693,439 worth of shares (112,429 units at $175.16) as part of a pre-agreed trading plan (SEC Form 4)
- New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence of Daily Oral F/TDF in HIV Prevention
Latest WINT
- TransCode Therapeutics Announces Leadership Transition
- Windtree Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form NT 10-K filed by Windtree Therapeutics Inc.
- Windtree Therapeutics Inc. filed SEC Form 8-K: Leadership Update
- Windtree Therapeutics Announces the Sale of its Cardiovascular Biotech Pipeline Drug Candidates
- Windtree Therapeutics Announces It Has Signed a Letter of Intent to Acquire CommLoan, Inc. a Revenue Generating Company in the Rapidly Growing Fintech Space
- Windtree Therapeutics Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- SEC Form 424B3 filed by Windtree Therapeutics Inc.
- SEC Form 10-Q filed by Windtree Therapeutics Inc.
- Windtree Therapeutics Announces It May Receive License Agreement Payments from Its Licensee for Renewed Acute Pulmonary Development by the Licensee